The goal of this study is to determine the overall layout of infiltrating immune repertoire in pediatric solid tumors. We will perform immune repertoire analysis and deconvolute immune components from RNA-seq data using transcript counts to infer the fraction of ~20 immune cell types infiltrating in pediatric tumors. As a comparator, we will do similar analyses on TCGA datasets. We will compare the associations of immune features with genomic parameters such as mutation burden, copy number alterations, molecular subtypes and signatures depending on the cancer type. We will also address whether immunegenomic subgroups correlate with clinic-pathological data, such as age, sex, overall and event free survival, stage of the disease, type of cancer, percentage of tumor content (if available), risk group, known pathological subtypes depending on the disease. In addition to CBTN datasets, we will analyze datasets from NCI TARGET, accessible through CAVATICA. We will analyze ~20 RNAseq data from hypermutant cancers and ~500 cases with pediatric brain tumor. We will analyze RNAseq data from ~90 cases of pediatric tumor who were treated with anti-PDL1, Atezolizumab
What are the goals of this project?
The goal of this study is to determine the overall layout of infiltrating immune repertoire in pediatric solid tumors.
The Children's Brain Tumor Network contributed to this project by providing access to the Pediatric Brain Tumor Atlas.
- Arash Nabbi, PharmD, PhD - University Health Network
- Dr. Uri Tabori, MD - The Hospital for Sick Children
- Dr. Stefan Pfister, MD - Hopp-Children’s Cancer Center, Germany
- Dr. Marcel Kool, PhD - Hopp-Children’s Cancer Center, Germany
- Dr. David Jones, PhD - Hopp-Children’s Cancer Center, Germany
- Dr. Jaeger, Hopp-Children’s Cancer Center, Germany
- Dr Katherine Hutchinson, PhD - Genentech
Delineating Pediatric Glioma Progression Using Single-nuclei Sequencing
Low-grade gliomas are the most prevalent brain cancer among children. While patients with this type of cancer respond well to surgery, the majority experience recurrence after initial resection, requiring additional rounds of treatment that are rarely guided by molecular information. Intra-tumour